Coverage-exclusion denials (the plan does not cover GLP-1s for obesity at all) cannot usually be appealed clinically
We combine physician oversight, comprehensive lab testing, prescription weight loss options, and in-person accountability
doi: 10.3390/nu13020351 [DOI] [PMC free article] [PubMed] [Google Scholar] 209
While further behind alcohol and nicotine research, preliminary studies are examining whether GLP-1 agonists could complement existing treatments like buprenorphine and naltrexone for opioid use disorder
Bottom Line Combining supplements with GLP-1 medications can enhance the effectiveness of your diabetes or weight management treatment
GLP-1 RAs could inhibit the expression of plasminogen activator inhibitor type-1 (PAI-1) and vascular adhesion molecule (VAM) in human vascular endothelial cells in vitro, which had a protective effect against endothelial cell dysfunction (ECD) in the early stages of diabetic vascular disease [32] and might explain the lower incidence of background and severe nonproliferative DR among individuals who used GLP-1 RAs
